Guei‐Sheung Liu

This paper develops an RNA base editor using CRISPR-Cas13 and ADAR2DD to correct mutations in inherited retinal diseases, showing up to 60% editing efficiency in vitro and partial rescue in mouse models.

This study evaluates platelet-derived extracellular vesicles (PEVs) loaded with kaempferol for treating corneal neovascularization, showing reduced vessel formation and inflammation in a mouse model.

This study characterizes the transcriptomic effects of Cas13bt3 in retinal cells and demonstrates its efficacy in silencing VEGFA mRNA in human retinal organoids and mouse models.

This study evaluates RNA-targeting CRISPR-Cas13 and engineered U1 systems to reduce mis-spliced ABCA4 variants in Stargardt disease, showing significant reductions in disease-causing splice variants.

The paper uses AI to identify genes associated with intraocular pressure by analyzing morphological changes in trabecular meshwork cells after gene knockouts.

This study uses gene knockouts and single-cell RNA sequencing to identify genetic networks contributing to elevated intraocular pressure in glaucoma.

This study analyzes the transcriptome and cellular landscape of aging retinas in AMD patients and controls, identifying age-related genes and cellular changes associated with AMD progression.

The paper identifies miR-143 as a protective miRNA in ischemia-induced retinal neovascularization using miRNA-Seq and RNA-Seq in a rat model.

This study develops a self-destructing CRISPR/Cas system for retinal gene editing, showing reduced SpCas9 mRNA and improved safety without compromising on-target efficiency.